Regeneron Inc., (Tarrytown, New York; NASDAQ:REGN) have announced third quarter net product sales of $244 million for Eylea (aflibercept) bringing total sales of the ocular treatment to $562 million in the first nine months of 2012. The drug, launched in the US in November 2011, is approved for both neovascular age related macular degeneration (AMD) and for macular edema following central retinal vein occlusion (CRVO). Commenting on the financial results Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron stated that, “the EYLEA launch continues to progress well and is driving strong sales and earnings growth. We now forecast 2012 U.S. Eylea net product sales of $790 to $815 million. With the recent approval of Eylea in the United States for the treatment of macular edema following central retinal vein occlusion (CRVO), and the anticipated launch beginning by the end of this year in Japan, Australia, and Europe, we expect Eylea to continue to drive growth through 2013 and beyond”.